Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Copernicus Capital Management, LLC Buys Pfizer Inc, Thermo Fisher Scientific Inc, Teladoc ...
05:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: PFE , TMO , TDOC , BMRN , JNJ , ALLO , VRTX , ATRA , ZNTL , TCRR , ACCD , JAZZ ,
Atara Biotherapeutics (NASDAQ:ATRA) Lowered to Hold at Zacks Investment Research
08:48am, Monday, 15'th Nov 2021 Dakota Financial News
Zacks Investment Research downgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a buy rating to a hold rating in a research note released on Thursday morning, Zacks.com reports. According to Zacks, Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle []
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
04:01pm, Monday, 08'th Nov 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript
03:13pm, Thursday, 04'th Nov 2021
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript
How Much Upside is Left in Atara Biotherapeutics (ATRA)? Wall Street Analysts Think 48%
12:13pm, Thursday, 04'th Nov 2021
The consensus price target hints at a 48.3% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
11:28am, Thursday, 04'th Nov 2021
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 2.17% and 1.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
07:30am, Monday, 04'th Oct 2021
SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06:14pm, Friday, 01'st Oct 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
03:30am, Wednesday, 29'th Sep 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) cl
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Friday, 03'rd Sep 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
08:30am, Thursday, 02'nd Sep 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript
10:50pm, Monday, 09'th Aug 2021
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
06:28pm, Monday, 09'th Aug 2021
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -3.41% and -38.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Monday, 02'nd Aug 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformativ
